PCSK9 Rejection Data
Jump to: Resources | Social Media Posts | About Prior Authorization
A letter from Dharmesh Patel, MD:
Too often, utilization management practices imposed by health plans and their pharmacy benefit managers get in the way of what is best for patients.
Perhaps the best recent example of cardiovascular innovation being roadblocked by payers is the PCSK9 inhibitor class. These cholesterol-lowering therapies can literally save lives – if patients can get them.
Unfortunately, new claims data shows that women, southerners and people of color can’t.
I encourage you to read the report in full -- and spread the word on social media.
Dharmesh Patel, MD
President, Partnership to Advance Cardiovascular Health
Resources
Social Share Graphics
Suggested Social Media
When trying to access a PCSK9 inhibitor, women are rejected 21% more often than men, according to recent claims data. Learn more in a new report from @advcardiohealth: https://bit.ly/3H3mtWY
Black patients are rejected at a 20% higher rate than white patients when they try to access a PCSK9 inhibitor, according to recent claims data. Read @advcardiohealth’s report to learn more: https://bit.ly/3H3mtWY
About Prior Authorization
For many patients, the process of identifying the right medication takes considerable effort. Imagine then how patients feel when their insurance company forces them to change their medication on the basis of cost.
The practice is called “non-medical switching.”
